Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Wu, Shu-ta
    • Other Affiliation: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, USA
  • Fowler, Anthony J
    • Other Affiliation: Department of Chemistry, University of North Carolina at Charlotte, Charlotte, USA
  • Garmon, Corey B
    • Other Affiliation: Department of Chemistry, University of North Carolina at Charlotte, Charlotte, USA
  • Fessler, Adam B
    • Other Affiliation: Department of Chemistry, University of North Carolina at Charlotte, Charlotte, USA
  • Ogle, Joshua D
    • Other Affiliation: Department of Chemistry, University of North Carolina at Charlotte, Charlotte, USA
  • Grover, Kajal R
    • Other Affiliation: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, USA
  • Allen, Bailey C
    • Other Affiliation: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, USA
  • Williams, Chandra D
    • Other Affiliation: Department of Animal Laboratory Resources, University of North Carolina at Charlotte, Charlotte, USA
  • Zhou, Ru
    • Other Affiliation: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, USA
  • Yazdanifar, Mahboubeh
    • Other Affiliation: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, USA
  • Ogle, Craig A
    • Other Affiliation: Department of Chemistry, University of North Carolina at Charlotte, Charlotte, USA
  • Mukherjee, Pinku
    • Other Affiliation: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, USA
Abstract
  • Abstract Background Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancers with a 5-year survival below 10%. Systemic delivery of chemotherapy drugs has severe side effects in patients with PDA and does not significantly improve overall survival rate. It is highly desirable to advance the therapeutic efficacy of chemotherapeutic drugs by targeting their delivery and increasing accumulation at the tumor site. MUC1 is a membrane-tethered glycoprotein that is aberrantly overexpressed in > 80% of PDA thus making it an attractive antigenic target. Methods Poly lactic-co-glycolic acid nanoparticles (PLGA NPs) conjugated to a tumor specific MUC1 antibody, TAB004, was used as a nanocarrier for targeted delivery into human PDA cell lines in vitro and in PDA tumors in vivo. The PLGA NPs were loaded with fluorescent imaging agents, fluorescein diacetate (FDA) and Nile Red (NR) or isocyanine green (ICG) for in vitro and in vivo imaging respectively or with a chemotherapeutic drug, paclitaxel (PTX) for in vitro cytotoxicity assays. Confocal microscopy was used to visualize internalization of the nanocarrier in vitro in PDA cells with high and low MUC1 expression. The in vivo imaging system (IVIS) was used to visualize in vivo tumor targeting of the nanocarrier. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was used to determine in vitro cell survival of cells treated with PTX-loaded nanocarrier. One-sided t-test comparing treatment groups at each concentration and two-way ANOVAs comparing internalization of antibody and PLGA nanoparticles. Results In vitro, TAB004-conjugated ICG-nanocarriers were significantly better at internalizing in PDA cells than its non-conjugated counterpart. Similarly, TAB004-conjugated PTX-nanocarriers were significantly more cytotoxic in vitro against PDA cells than its non-conjugated counterpart. In vivo, TAB004-conjugated ICG-nanocarriers showed increased accumulation in the PDA tumor compared to the non-conjugated nanocarrier while sparing normal organs. Conclusions The study provides promising data for future development of a novel MUC1-targeted nanocarrier for direct delivery of imaging agents or drugs into the tumor microenvironment.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • The Author(s).
Journal title
  • BMC Cancer
Journal volume
  • 18
Journal issue
  • 1
Page start
  • 457
Language
  • English
Bibliographic citation
  • BMC Cancer. 2018 Apr 23;18(1):457
Publisher
  • BioMed Central

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 12885_2018_article_4393.pdf 2019-05-07 Public Download
file details 12885_2018_4393_moesm1_esm.jpg 2019-05-07 Public Download
file details 12885_2018_4393_moesm2_esm.jpg 2019-05-07 Public Download